TYMS and colorectal carcinoma: The clinical significance of TSER genotypes remains largely unproven in CRC; however, prospective selection of patients with gastric cancer have at least one TSER*2 allele favoring lower TYMS expression therapy resulted in an encouraging disease control rate for treatment with FOLFOX[82].